Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
äŒæ¥ã³ãŒãGPCR
äŒç€ŸåStructure Therapeutics Inc
äžå Žæ¥Feb 03, 2023
æé«çµå¶è²¬ä»»è
ãCEOãStevens (Raymond)
åŸæ¥å¡æ°163
蚌åžçš®é¡Depository Receipt
æ±ºç®ææ«Feb 03
æ¬ç€Ÿæåšå°601 Gateway Blvd Suite 900
éœåžSOUTH SAN FRANCISCO
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94080
é»è©±çªå·16504571978
ãŠã§ããµã€ãhttps://structuretx.com/
äŒæ¥ã³ãŒãGPCR
äžå Žæ¥Feb 03, 2023
æé«çµå¶è²¬ä»»è
ãCEOãStevens (Raymond)